Sanofi India Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ah8rdqdwf3eccynopib11t4x.pdf

Key Takeaways


The Demerger: Two Listed Entities

Hrosz: "We think that we can maximize the Sanofi India's potential and our current India for India plans potential by giving each of these segments specific capabilities, removing unnecessary and intertwined processes that today exist and fully aligning these businesses with the respective global structures."

India-for-India Strategy & Restructuring


CHC Business: Ambition & Economics

Hrosz: "India is a very important key market for consumer healthcare in general. It is number six. It ranks number six for consumer healthcare globally. For Sanofi, it ranks already number 10. Even if you see already a gap there, even 10 is already very relevant."

General Medicines: Focus Areas


Margin Dynamics & Sustainability

Karandikar: "In the last investor call also we made the statement that the operating profit percentage to sales will remain constant. So it's not just gross margins, the operating profit percentage will remain constant. So we will adjust the purchase prices accordingly."

Guidance & Commitments

CommitmentSpecificsTimeline
Demerger closureTwo listed entities: Sanofi India Ltd (GenMed) and Sanofi Consumer Healthcare India Ltd; 1:1 share swap; Sanofi holds 60.4% in bothMid-2024, subject to approvals
CHC margin premiumCHC margins always 8% to 10% higher than blended marginsOngoing
Operating profit protectionOperating profit percentage to sales remains constant through NLEM price impacts, via purchase price adjustmentsOngoing; transitionary inventory impact possible
Dividend payoutMaintain payout ratios going forward under India-for-India strategyOngoing
Renewable energy100% renewable energyBy 2030
Net zeroCarbon net zeroBy 2045

Key Metrics

MetricQ1 CY23 (Q4 FY23)
Revenue₹2,620 cr in CY22; Q1 CY23 comparable sales growth of 9% YoY
Operating profit growth21% YoY in Q1 CY23
Operating profit growth (QoQ)40% vs Q4 CY22
EBITDA margin31%, a record quarter
Consolidated operating profit margin25%–26% range
Profit before tax growth (Q4 CY22)22% YoY
Dividend payout ratio85% (last payout)
Dividend yield~3%–3.5%
Consumer healthcare revenue share~28% of total business, turnover of ~₹700 cr annually
Consumer healthcare historical growth~8%–8.5% CAGR from 2018 onwards
Consumer healthcare margin premium8%–10% higher than blended consolidated margins
Diabetes sales force~2x resources deployed vs prior
NLEM price impact timingNot in Q1 CY23; Lantus impact from April (Q2 CY23) onwards
Total shareholder returns (2010–2023)5x, CAGR of 12.2%